Home Companies Catalysts Deep Dives
Descovy emtricitabine/tenofovir alafenamide APPROVED
Drug Profile
ModalitySmall molecule
RoutePO
Therapy AreaInfectious Disease
Launch2016-04-04
US LOE2032-04-04
Peak Sales Est$2500M
Formulations[{"id":"descovy-tablet","route":"PO","setting":"PATIENT_SELF","frequency":"Once daily","is_primary":
Companies
GILD (ORIGINATOR)100%
Mechanism: Nucleotide reverse transcriptase inhibitor (NtRTI)
Expert: Prodrug of tenofovir that inhibits HIV reverse transcriptase.
Everyday: Blocks HIV enzyme needed to copy viral genetic material.
Targets: ["HIV RT"]
Revenue History
PeriodRevenue ($M)
2023$1,990M
2024$2,113M
Q1 2025$585M
Q2 2025$653M
Q3 2025$701M
Q4 2025$819M
2025$2,800M
Programs (2)
IndicationStageKey StudyRegional Status
HIV-1 treatmentAPPROVEDGS-US-311-1089[{"stage":"APPROVED","region":"US","approval_date":"2016-04-04"}]
HIV-1 PrEPAPPROVEDDISCOVER[{"stage":"APPROVED","region":"US","approval_date":"2019-10-03"}]
Notes
Backbone for HIV treatment and approved for PrEP.
Data from Supabase · Updated 2026-03-24